Akebia Therapeutics, Inc. (NASDAQ:AKBA – Get Rating) was the target of a significant decrease in short interest in March. As of March 31st, there was short interest totalling 5,660,000 shares,  a decrease of 15.3% from the March 15th total of 6,680,000 shares. Based on an average daily volume of 2,020,000 shares, the short-interest ratio is currently 2.8 days.

In other news, CEO John P. Butler sold 91,868 shares of the company’s stock in a transaction on Wednesday, March 1st. The stock was sold at an average price of $0.88, for a total transaction of $80,843.84. Following the transaction, the chief executive officer now directly owns 1,568,872 shares of the company’s stock, valued at $1,380,607.36. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Over the last three months, insiders have sold 132,524 shares of company stock valued at $116,621. Corporate insiders own  3.68% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of AKBA. Alerce Investment Management L. P. raised its holdings in  Akebia Therapeutics by 224.3% in the 4th quarter. Alerce Investment Management L.P. now owns 15,090,119 shares of the biopharmaceutical company’s stock valued at $8,707,000 after acquiring an additional 10,437,558 shares during the last quarter.  Millennium Management LLC raised its holdings in  Akebia Therapeutics by 65.8% in the 2nd quarter. Millennium Management LLC now owns 5,354,175 shares of the biopharmaceutical company’s stock valued at $1,891,000 after acquiring an additional 2,124,161 shares during the last quarter.  Renaissance Technologies LLC raised its holdings in  Akebia Therapeutics by 103.5% in the 3rd quarter. Renaissance Technologies LLC now owns 3,016,427 shares of the biopharmaceutical company’s stock valued at $954,000 after acquiring an additional 1,534,127 shares during the last quarter.  Jacobs Levy Equity Management Inc. increased its holdings in shares of  Akebia Therapeutics by 162.7% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 2,042,816 shares of the biopharmaceutical company’s stock worth $646,000 after buying an additional 1,265,199 shares during the last quarter.  Finally, Vanguard Group Inc. increased its holdings in shares of  Akebia Therapeutics by 8.8% during the 1st quarter. Vanguard Group Inc. now owns 14,402,988 shares of the biopharmaceutical company’s stock worth $10,339,000 after buying an additional 1,167,319 shares during the last quarter. 28.13% of the stock is owned by hedge funds and other institutional investors.

AKBA stock opened at $0.68 on Wednesday. The company’s 50-day simple moving average is $0.74 and its 200-day simple moving average is $0.54. The company has a quick ratio of 1.31, a current ratio of 1.48 and a debt-to-equity ratio of 3.65. Akebia Therapeutics has a 52-week low of $0.24 and a 52-week high of $1.20. The firm has a market cap of $125.70 million, a P/E ratio of -1.31 and a beta of 0.73.

Several research firms recently issued reports on AKBA. HC Wainwright  reissued a “neutral” rating and issued a $1.25 target price on shares of Akebia Therapeutics in a research report on Friday, March 31st. StockNews.com initiated coverage on shares of Akebia Therapeutics in a report on Friday, March 17th. They issued a “buy” rating on the stock.

Akebia Therapeutics, Inc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat.

Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.